Screener
Alto Neuroscience ANRO Business Segments — Personnel expenses excluding stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Personnel expenses excluding stock-based compensation | $6,249 | $5,783 |
| Stock-based compensation | 2,824 | 1,968 |
| Direct external program expenses: | ||
| ALTO-100 | 1,764 | 1,124 |
| ALTO-300 | 1,507 | 922 |
| ALTO-101 | 5,356 | 969 |
| ALTO-203 | 6 | 737 |
| ALTO-207 | 4,143 | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation?
- Alto Neuroscience (ANRO) reported business segments — personnel expenses excluding stock-based compensation of $6.25M in Q1 2026.
- How has Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation changed year-over-year?
- Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation increased by 8.1% year-over-year, from $5.78M to $6.25M.
- What is the long-term trend for Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation?
- Over 2 years (2023 to 2025), Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation has grown at a 26.2% compound annual growth rate (CAGR), from $13.38M to $21.32M.
- What does business segments — personnel expenses excluding stock-based compensation mean?
- This metric represents the cash-based compensation costs, including salaries, bonuses, and benefits, for employees directly associated with the company's primary business operations. It excludes non-cash equity awards to provide a clearer view of the recurring operational cash burn required to maintain the workforce. Monitoring this helps investors assess the core human capital investment required to advance clinical-stage biopharmaceutical programs.
Ask your AI about Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude